Skip to main navigation
  • Our Science
  • AT-527
  • COVID-19
  • About Atea
    • About Us
    • Pipelines & Programs
    • Leadership
  • Investors
    • Overview
    • News & Events
      • News Releases
      • Events & Presentations
      • Publications
    • Financials
      • SEC Filings
      • Annual Reports
      • Quarterly Reports
    • Stock Info
      • Stock Quote & Chart
      • Historical Price Look up
      • Analyst Coverage
    • Corporate Governance
      • Documents & Charters
      • Management Team
      • Board of Directors
      • Committee Composition
    • Shareholder Resources
      • Investor FAQs
      • Email Alerts
      • Contact IR
      • RSS Feeds
  • Careers
  • Contact
The tip of a pipette pointing towards droplets suspended in a green solution.

Investor Relations

Committee Composition

Breadcrumb

  1. Investors
  2. Committee Composition

Committee Composition

Audit Committee Compensation Committee Nominating and Corporate Governance Committee Strategy and Public Policy Committee
Jerome Adams, M.D., M.P.H. Nominating and Corporate Governance Committee Strategy and Public Policy Committee
Franklin Berger Audit Committee Compensation Committee
Barbara Duncan Audit Committee Nominating and Corporate Governance Committee
Bruno Lucidi Audit Committee Compensation Committee
Polly A. Murphy, D.V.M., Ph.D. Nominating and Corporate Governance Committee Strategy and Public Policy Committee
Bruce Polsky, M.D Compensation Committee Strategy and Public Policy Committee
= Chairperson = Member
Investor FAQs
RSS Feeds
Email Alerts
Contact IR

Atea is a clinical-stage biopharmaceutical company working to address unmet medical needs through novel antiviral treatment.

  • Atea Pharmaceuticals, Inc.
  • 225 Franklin Street
  • Suite 2100
  • Boston, MA 02110
  • (857) 284-8891

Copyright © 2023 By Atea Pharmaceuticals, Inc. All Rights Reserved. Privacy Policy | Terms of Use